Stockreport

Royalty Pharma Reports Second Quarter 2025 Results

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF Portfolio Receipts growth of 20% to $727 million; Royalty Receipts growth of 11%Net cash provided by operating activities of $364 millionRaised full year 2025 guidance: [Read more]